ClinicalTrials.gg

Program

centanafadine hydrochloride

Also written as “Centanafadine”, “Centanafadine SR” and “EB-1020 (Centanafadine) 164.4 mg”.

Its studies are mostly in Attention Deficit Disorder with Hyperactivity · Depressive Disorder, Major · Drug Misuse · Binge-Eating Disorder · Smoking Cessation, led by Otsuka.

Furthest: phase 3, since Jun 28, 201825 company-led studies, 5 open or runningNext primary completion: May 27, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka255 open or runningphase 3since Jun 28, 2018Nov 19, 2012May 27, 2027phase 3 · NCT07759154

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Nov 19, 2012.

  1. Feb 25, 2021Phase 1 study in Attention Deficit Disorder with HyperactivityNCT04786730 · 50 enrolled · United States
  2. Sep 23, 2021Phase 2 study in Smoking CessationNCT05066724 · 50 enrolled · United States
  3. Oct 7, 2021Phase 2 study in Binge-Eating DisorderNCT05113953 · 147 enrolled · United States
  4. Feb 16, 2022Phase 3 study in Attention Deficit Disorder with HyperactivityNCT05257265 · 459 enrolled · United States
  5. Mar 4, 2022Phase 3 study in Attention Deficit Disorder with HyperactivityNCT05279313 · 680 enrolled · United States, Canada, Puerto Rico
  6. Jun 16, 2022Phase 3 study in Attention Deficit Disorder with HyperactivityNCT05428033 · 574 enrolled · United States
  7. Sep 7, 2022Phase 2 study in Depressive Disorder, MajorNCT05536414 · 337 enrolled · United States
  8. Apr 9, 20252 phase 3 studies in Attention Deficit Disorder with HyperactivityNCT06931080, NCT06926829
  9. May 7, 2025Phase 3 study in Attention Deficit Disorder with HyperactivityNCT06973577 · 315 enrolled · United States, Puerto Rico
  10. Jul 17, 20252 phase 3 studies in Attention Deficit Disorder with HyperactivityNCT07086313, NCT07087327
  11. Nov 19, 2025Phase 1 study in Attention Deficit Disorder with HyperactivityNCT07253441 · 174 enrolled · United States
  12. Dec 18, 2025Phase 1 study in Attention Deficit Disorder with HyperactivityNCT07314333 · 40 enrolled · United States
  13. Mar 6, 20262 phase 1 studiesNCT07465731, NCT07486895
  14. Aug 6, 2026Phase 3 study in Attention Deficit Disorder with HyperactivityNCT07759154 · 80 planned · United States

Ahead

  1. May 27, 2027Primary completion: phase 3 study in Attention Deficit Disorder with HyperactivityNCT07759154
  2. Aug 2027Primary completion: phase 3 study in Attention Deficit Disorder with HyperactivityNCT07087327
  3. Aug 2027Primary completion: phase 3 study in Attention Deficit Disorder with HyperactivityNCT07086313
  4. Dec 2027Primary completion: phase 3 study in Attention Deficit Disorder with HyperactivityNCT06926829

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07759154Attention Deficit Disorder with Hyperactivity · United States3RecruitingMay 27, 202780
NCT07486895Attention Deficit Disorder with Hyperactivity · United States1CompletedMay 18, 202344
NCT07465731Healthy Volunteers · United States1CompletedMar 26, 202362
NCT07314333Attention Deficit Disorder with Hyperactivity · United States1CompletedMar 30, 202640
NCT07253441Attention Deficit Disorder with Hyperactivity · United States1CompletedDec 30, 2024174
NCT07087327Attention Deficit Disorder with Hyperactivity · Japan3RecruitingAug 2027180
NCT07086313Attention Deficit Disorder with Hyperactivity · Japan3RecruitingAug 2027315
NCT06973577Attention Deficit Disorder with Hyperactivity · United States, Puerto Rico3CompletedApr 22, 2026315
NCT06926829Attention Deficit Disorder with Hyperactivity · Japan3RecruitingDec 2027180
NCT06931080Attention Deficit Disorder with Hyperactivity · Japan3RecruitingDec 2027630
NCT05536414Depressive Disorder, Major · United States2CompletedMay 16, 2025337
NCT05428033Attention Deficit Disorder with Hyperactivity · United States3CompletedMar 17, 2025574
NCT05279313Attention Deficit Disorder with Hyperactivity · United States, Canada, Puerto Rico3CompletedApr 24, 2026680
NCT05257265Attention Deficit Disorder with Hyperactivity · United States3CompletedSep 29, 2023459
NCT05113953Binge-Eating Disorder · United States2CompletedAug 19, 2022147
NCT05066724Smoking Cessation · United States2CompletedMay 31, 202250
NCT04786730Attention Deficit Disorder with Hyperactivity · United States1CompletedApr 26, 202350
NCT04398225Attention Deficit Disorder with Hyperactivity · United States1CompletedApr 1, 202132
NCT04081363Attention Deficit Disorder with Hyperactivity · United States2CompletedDec 21, 201913
NCT03605849Attention Deficit Disorder with Hyperactivity · United States3CompletedSep 7, 2021662
NCT03605836Attention Deficit Disorder with Hyperactivity · United States3CompletedMay 14, 2020590
NCT03605680Attention Deficit Disorder with Hyperactivity · United States3CompletedApr 11, 2020604
NCT02827513Attention Deficit Disorder with Hyperactivity · Australia1TerminatedJan 201616
NCT02144415Drug Misuse · United States1CompletedJul 1, 201480
NCT01744808Normal, Healthy Volunteers · Australia1CompletedFeb 1, 201454

How it is read

Names in the registry

  • “Centanafadine”, 9 entries
  • “Centanafadine SR”, 6 entries
  • “EB-1020 (Centanafadine) 164.4 mg”, 2 entries
  • “EB-1020 (Centanafadine) 328.8 mg”, 2 entries
  • “Centanafadine Hydrochloride”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.